Report on webinar series cell and gene therapy: from concept to clinical use

Christopher F. van der Walle; Christine Dufès; Arpan S. Desai; Julie Kerby; Joanne Broadhead; Alice Tam; Zahra Rattray

doi:10.3390/pharmaceutics14010168

Report on webinar series cell and gene therapy: from concept to clinical use

Christopher F. van der Walle
, Christine Dufès
, Arpan S. Desai
, Julie Kerby
, Joanne Broadhead
, Alice Tam
, Zahra Rattray

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

94 Downloads (Pure)

Abstract

With the launch of the UK Academy of Pharmaceutical Sciences Advanced Therapy Medicinal Products Focus Group in late 2020, a webinar series reviewing the current and emerging trends in cell and gene therapy was held virtually in May 2021. This webinar series was timely given the recent withdrawal of the United Kingdom from the European Union and the global COVID-19 pandemic impacting all sectors of the pharmaceutical sciences research landscape globally and in the UK. Delegates from the academic, industry, regulatory and NHS sectors attended the session where challenges and opportunities in the development and clinical implementation of cell and gene therapies were discussed. Globally, the cell and gene therapy market has reached a value of 4.3 billion dollars in 2020, having increased at a compound annual growth rate of 25.5% since 2015. This webinar series captured all the major developments in this rapidly-evolving area and highlighted emerging concepts warranting cross-sector efforts from across the community in the future.

Original language	English
Article number	168
Number of pages	10
Journal	Pharmaceutics
Volume	14
Issue number	1
Early online date	11 Jan 2022
DOIs	https://doi.org/10.3390/pharmaceutics14010168
Publication status	Published - 11 Jan 2022

Funding

Funding: Rattray acknowledges funding of her research by the UKRI Engineering and Physical Sciences Research Council (EPSRC) grant number EP/V028960/1. Acknowledgments: The authors acknowledge support from the Academy of Pharmaceutical Sciences and the Advanced Therapy Medicinal Products Focus group. We also thank our useful discussions with Frank Thielmann, Andrew Donnelly, Tejash Shah, and Alain Pluen that led to planning of the symposium. We also acknowledge support from Nicholas JW Rattray and Biorender in creating Figure 1.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 9 Industry, Innovation, and Infrastructure

Keywords

cell therapy
gene therapy
similars
manufacture
in vivo gene therapy
viral vectors

Access to Document

10.3390/pharmaceutics14010168Licence: CC BY 4.0

van-der-Walle-etal-Pharmaceutics-2021-Report-on-webinar-series-cell-and-gene-therapyFinal published version, 12 MBLicence: CC BY 4.0

Cite this

@article{4366fbe2c64b462d93b99d4b6e85f871,

title = "Report on webinar series cell and gene therapy: from concept to clinical use",

abstract = "With the launch of the UK Academy of Pharmaceutical Sciences Advanced Therapy Medicinal Products Focus Group in late 2020, a webinar series reviewing the current and emerging trends in cell and gene therapy was held virtually in May 2021. This webinar series was timely given the recent withdrawal of the United Kingdom from the European Union and the global COVID-19 pandemic impacting all sectors of the pharmaceutical sciences research landscape globally and in the UK. Delegates from the academic, industry, regulatory and NHS sectors attended the session where challenges and opportunities in the development and clinical implementation of cell and gene therapies were discussed. Globally, the cell and gene therapy market has reached a value of 4.3 billion dollars in 2020, having increased at a compound annual growth rate of 25.5\% since 2015. This webinar series captured all the major developments in this rapidly-evolving area and highlighted emerging concepts warranting cross-sector efforts from across the community in the future.",

keywords = "cell therapy, gene therapy, similars, manufacture, in vivo gene therapy, viral vectors",

author = "\{van der Walle\}, \{Christopher F.\} and Christine Duf{\`e}s and Desai, \{Arpan S.\} and Julie Kerby and Joanne Broadhead and Alice Tam and Zahra Rattray",

year = "2022",

month = jan,

day = "11",

doi = "10.3390/pharmaceutics14010168",

language = "English",

volume = "14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "MDPI AG",

number = "1",

}

TY - JOUR

T1 - Report on webinar series cell and gene therapy

T2 - from concept to clinical use

AU - van der Walle, Christopher F.

AU - Dufès, Christine

AU - Desai, Arpan S.

AU - Kerby, Julie

AU - Broadhead, Joanne

AU - Tam, Alice

AU - Rattray, Zahra

PY - 2022/1/11

Y1 - 2022/1/11

N2 - With the launch of the UK Academy of Pharmaceutical Sciences Advanced Therapy Medicinal Products Focus Group in late 2020, a webinar series reviewing the current and emerging trends in cell and gene therapy was held virtually in May 2021. This webinar series was timely given the recent withdrawal of the United Kingdom from the European Union and the global COVID-19 pandemic impacting all sectors of the pharmaceutical sciences research landscape globally and in the UK. Delegates from the academic, industry, regulatory and NHS sectors attended the session where challenges and opportunities in the development and clinical implementation of cell and gene therapies were discussed. Globally, the cell and gene therapy market has reached a value of 4.3 billion dollars in 2020, having increased at a compound annual growth rate of 25.5% since 2015. This webinar series captured all the major developments in this rapidly-evolving area and highlighted emerging concepts warranting cross-sector efforts from across the community in the future.

AB - With the launch of the UK Academy of Pharmaceutical Sciences Advanced Therapy Medicinal Products Focus Group in late 2020, a webinar series reviewing the current and emerging trends in cell and gene therapy was held virtually in May 2021. This webinar series was timely given the recent withdrawal of the United Kingdom from the European Union and the global COVID-19 pandemic impacting all sectors of the pharmaceutical sciences research landscape globally and in the UK. Delegates from the academic, industry, regulatory and NHS sectors attended the session where challenges and opportunities in the development and clinical implementation of cell and gene therapies were discussed. Globally, the cell and gene therapy market has reached a value of 4.3 billion dollars in 2020, having increased at a compound annual growth rate of 25.5% since 2015. This webinar series captured all the major developments in this rapidly-evolving area and highlighted emerging concepts warranting cross-sector efforts from across the community in the future.

KW - cell therapy

KW - gene therapy

KW - similars

KW - manufacture

KW - in vivo gene therapy

KW - viral vectors

UR - https://www.mdpi.com/journal/pharmaceutics

U2 - 10.3390/pharmaceutics14010168

DO - 10.3390/pharmaceutics14010168

M3 - Article

SN - 1999-4923

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 1

M1 - 168

ER -

Report on webinar series cell and gene therapy: from concept to clinical use

Abstract

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Multiscale Metrology Suite for Next-generation Healthcare Technologies (EPSRC Strategic Equipment)

Cite this

Report on webinar series cell and gene therapy: from concept to clinical use

Abstract

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Projects

Multiscale Metrology Suite for Next-generation Healthcare Technologies (EPSRC Strategic Equipment)

Cite this